All Stories

  1. Zinc–amino-acid conjugate supplementation shapes maternal and infant gut microbiomes—a pilot study
  2. Synaptic protein mutations in autism
  3. Is autism a developmental zinc deficiency?
  4. Fluorescent Probes for Metal Ion Detection
  5. Foundations of Brain Metallomics
  6. Targeting Platelet Activating Factor Signaling for Therapeutic Benefits in Neurodegenerative Disorders
  7. Metal Dyshomeostasis as a Driver of Gut Pathology in Autism Spectrum Disorders
  8. Application of Human Plasma Targeted Lipidomics and Analysis of Toxic Elements to Capture the Metabolic Complexities of Hypothyroidism
  9. Zinc signaling controls astrocyte‐dependent synapse modulation via the PAF receptor pathway
  10. Neuroprotective Benefits of Rosmarinus officinalis and Its Bioactives against Alzheimer’s and Parkinson’s Diseases
  11. Polar lipids modify Alzheimer’s Disease pathology by reducing astrocyte pro-inflammatory signaling through platelet-activating factor receptor (PTAFR) modulation
  12. Secondary Modification of S100B Influences Anti Amyloid-β Aggregation Activity and Alzheimer’s Disease Pathology
  13. The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome—Plant Metabolites in IBS Treatment
  14. Consensus recommendations on chewing, swallowing and gastrointestinal problems in Phelan-McDermid syndrome
  15. Dissecting the 22q13 region to explore the genetic and phenotypic diversity of patients with Phelan-McDermid syndrome
  16. The use of organoids in food research
  17. The Rationale for Vitamin, Mineral, and Cofactor Treatment in the Precision Medical Care of Autism Spectrum Disorder
  18. Editorial: Interactions of the nervous system with bacteria, volume II
  19. Identification of Nanoparticle Properties for Optimal Drug Delivery across a Physiological Cell Barrier
  20. Metal Profiles in Autism Spectrum Disorders: A Crosstalk between Toxic and Essential Metals
  21. The Role of Dietary Lipids in Cognitive Health: Implications for Neurodegenerative Disease
  22. Identification of the common neurobiological process disturbed in genetic and non-genetic models for autism spectrum disorders
  23. Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients
  24. Non-Genetic Modifiers of Synaptic Plasticity and Neurotransmission in the Central Nervous System (CNS) in Health and Disease
  25. Prevalence of low dietary zinc intake in women and pregnant women in Ireland
  26. Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments
  27. Atherosclerosis fate in the era of tailored functional foods: Evidence-based guidelines elicited from structure- and ligand-based approaches
  28. Prenatal Zinc Deficient Mice as a Model for Autism Spectrum Disorders
  29. Anti-inflammatory and antioxidant activities of polar lipids in vitro and implications for neurodegenerative disease
  30. Zinc is a key regulator of gastrointestinal development, microbiota composition and inflammation with relevance for autism spectrum disorders
  31. Localizing Therapeutics to the Brain
  32. S100B dysregulation during brain development affects synaptic SHANK protein networks via alteration of zinc homeostasis
  33. Autism Spectrum Disorders
  34. Autism Spectrum Disorders: Etiology and Pathology
  35. The Metallome as a Link Between the “Omes” in Autism Spectrum Disorders
  36. Expression Analysis of Zinc Transporters in Nervous Tissue Cells Reveals Neuronal and Synaptic Localization of ZIP4
  37. Editorial: Interactions of the Nervous System With Bacteria
  38. Sperm selection by rheotaxis improves sperm quality and early embryo development
  39. Activation of the medial preoptic area (MPOA) ameliorates loss of maternal behavior in a Shank2 mouse model for autism
  40. Altered gut–brain signaling in autism spectrum disorders—from biomarkers to possible intervention strategies
  41. IPSC-derived intestinal organoids and current 3D intestinal scaffolds
  42. Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer’s Disease
  43. Rho GTPases in the Amygdala—A Switch for Fears?
  44. Comparing nanoparticles for drug delivery: The effect of physiological dispersion media on nanoparticle properties
  45. Concentrations of Essential Trace Metals in the Brain of Animal Species—A Comparative Study
  46. Autism-associated SHANK3 mutations impair maturation of neuromuscular junctions and striated muscles
  47. Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment
  48. Drug delivery across the blood–brain barrier: recent advances in the use of nanocarriers
  49. Metals and amyloid gain-of-toxic mechanisms in neurodegenerative diseases
  50. Metallic-based nanocarriers: methods employed in nanoparticle characterization and assessing the interaction with the blood–brain barrier
  51. Biometals and nutrition in autism spectrum disorders
  52. Measuring biometals
  53. Extracerebral biometals in autism spectrum disorders: the gut–brain axis
  54. Biometals in Autism Spectrum Disorders
  55. Introduction to metallomics: the science of biometals
  56. Human stem cell models linking biometal abnormalities and autism
  57. Animal models for trace metal abnormalities—links to autism
  58. Linking trace metal abnormalities to autism—insights from epidemiological studies
  59. The history of metals in autism spectrum disorders
  60. The specific role of zinc in autism spectrum disorders
  61. Biometal homeostasis as a therapeutic strategy in autism spectrum disorders
  62. Future perspectives: autism, a disorder of biometal imbalance?
  63. Nonessential metals and their brain pathology
  64. Animal models for autism—links to biometal abnormalities
  65. Essential trace metals and their function in brain development
  66. Zinc Deficiency During Pregnancy Leads to Altered Microbiome and Elevated Inflammatory Markers in Mice
  67. The Role of Trace Metals in Alzheimer’s Disease
  68. Nanomedicine Against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence
  69. ROS-responsive “smart” polymeric conjugate: Synthesis, characterization and proof-of-concept study
  70. Distribution and Relative Abundance of S100 Proteins in the Brain of the APP23 Alzheimer’s Disease Model Mice
  71. Altered Intestinal Morphology and Microbiota Composition in the Autism Spectrum Disorders Associated SHANK3 Mouse Model
  72. Shank3 Transgenic and Prenatal Zinc-Deficient Autism Mouse Models Show Convergent and Individual Alterations of Brain Structures in MRI
  73. Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives
  74. Prospects of Zinc Supplementation in Autism Spectrum Disorders and Shankopathies Such as Phelan McDermid Syndrome
  75. Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain
  76. Zinc Binding to S100B Affords Regulation of Trace Metal Homeostasis and Excitotoxicity in the Brain
  77. Brain Lateralization in Mice Is Associated with Zinc Signaling and Altered in Prenatal Zinc Deficient Mice That Display Features of Autism Spectrum Disorder
  78. Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer’s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery
  79. De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability
  80. Corrigendum to: EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION (International Journal of Pharmaceutics. 511 (1) (2016) 331-340)
  81. Characterization of zinc amino acid complexes for zinc delivery in vitro using Caco-2 cells and enterocytes from hiPSC
  82. Nanomedicine and Neurodegenerative Diseases: An Introduction to Pathology and Drug Targets
  83. Object Phobia and Altered RhoA Signaling in Amygdala of Mice Lacking RICH2
  84. Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates
  85. Zinc deficiency and low enterocyte zinc transporter expression in human patients with autism related mutations in SHANK3
  86. Molecular and Cellular Mechanisms of Synaptopathies
  87. Zinc in Autism
  88. Extracerebral Dysfunction in Animal Models of Autism Spectrum Disorder
  89. EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION
  90. Zinc Deficiency
  91. Activity and circadian rhythm influence synaptic Shank3 protein levels in mice
  92. The Shank3 Interaction Partner ProSAPiP1 Regulates Postsynaptic SPAR Levels and the Maturation of Dendritic Spines in Hippocampal Neurons
  93. Enlarged dendritic spines and pronounced neophobia in mice lacking the PSD protein RICH2
  94. Gender Dependent Evaluation of Autism like Behavior in Mice Exposed to Prenatal Zinc Deficiency
  95. Nanoparticle transport across the blood brain barrier
  96. Cellular Zinc Homeostasis Contributes to Neuronal Differentiation in Human Induced Pluripotent Stem Cells
  97. Actin-Dependent Alterations of Dendritic Spine Morphology in Shankopathies
  98. Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
  99. Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
  100. Behavioral impairments in animal models for zinc deficiency
  101. N-cadherin-mediated cell adhesion is regulated by extracellular Zn2+
  102. Effects of Trace Metal Profiles Characteristic for Autism on Synapses in Cultured Neurons
  103. Zinc in Gut-Brain Interaction in Autism and Neurological Disorders
  104. Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release
  105. Loss of COMMD1 and copper overload disrupt zinc homeostasis and influence an autism-associated pathway at glutamatergic synapses
  106. The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation
  107. Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport
  108. Characterization of biometal profiles in neurological disorders
  109. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution
  110. Zinc deficiency dysregulates the synaptic ProSAP/Shank scaffold and might contribute to autism spectrum disorders
  111. A role for synaptic zinc in ProSAP/Shank PSD scaffold malformation in autism spectrum disorders
  112. Environmental Factors in Autism
  113. Nanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems
  114. The Nedd4-binding protein 3 (N4BP3) is crucial for axonal and dendritic branching in developing neurons
  115. Autism-Associated Mutations in ProSAP2/Shank3 Impair Synaptic Transmission and Neurexin-Neuroligin-Mediated Transsynaptic Signaling
  116. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2
  117. Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies
  118. Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
  119. Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
  120. Development of Novel Zn2+ Loaded Nanoparticles Designed for Cell-Type Targeted Drug Release in CNS Neurons: In Vitro Evidences
  121. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation
  122. Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold
  123. Rare Feeding Behavior of Great-Tailed Grackles (Quiscalus mexicanus) in the Extreme Habitat of Death Valley~!2010-01-08~!2010-03-08~!2010-05-21~!
  124. Abstract 3480: XIAP inhibitors prime glioblastoma cells for γ-irradiation-induced apoptosis and circumvent radioresistance of glioblastoma stem cells
  125. Synaptogenesis of hippocampal neurons in primary cell culture
  126. Synaptic Cross-talk betweenN-Methyl-d-aspartate Receptors and LAPSER1-β-Catenin at Excitatory Synapses
  127. Small-Molecule XIAP Inhibitors Enhance γ-Irradiation-Induced Apoptosis in Glioblastoma
  128. Efficient targeting of proteins to post-synaptic densities of excitatory synapses using a novel pSDTarget vector system